drugset / Trial / NCT01989026

A Randomized Trial of Providing BCG Vaccination Immediately

NCT01989026 ↗

Phase 4 Terminated 3361 enrolled Bandim Health Project
RandomizedParallel-groupSingle-blindPrevention

Summary

Recent studies show that BCG vaccination reduces neonatal mortality by more than 40%. This effect cannot be explained by prevention of tuberculosis, which is very rare among infants. The protective effect of BCG vaccination is seen already within the first week. It seems that BCG provides a non-specific beneficial immune modulation - thereby reducing overall mortality. Mortality is very high among newborns admitted to the neonatal intensive care unit. If BCG has immediate beneficial effects on the immune system, vaccinating children with BCG as early as possible may save lives. The investigators will test this hypothesis in a randomized trial among newborns in Guinea-Bissau, randomizing newborns admitted to the neonatal intensive care unit at the National Hospital 1:1 to BCG immediately or at discharge (usual practice).

Timeline

Start
2013-10
Primary completion
2017-10-01
Completion
2017-10-01

Outcome

Outcome not reported

Stopped: “Major structural and organizational changes at the NICU”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bacille Calmette-Guérin Vaccine 0.05 ml Other

Indications

No indication recorded.